Zynerba Sketches Phase III Plan For Cannabinoid Gel In Fragile X
Positive Phase II study of cannabinoid ZYN002 sends stock soaring, but the trial was very small with an open-label design, and response was mostly recorded by caregivers.
Positive Phase II study of cannabinoid ZYN002 sends stock soaring, but the trial was very small with an open-label design, and response was mostly recorded by caregivers.